The isolation of an RNA aptamer targeting to p53 protein with single amino acid mutation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 32, 2015, Pages 10002-10007

  Chen, Liang ^a   Rashid, Farooq ^a   Shah, Abdullah ^a   Awan, Hassaan M ^a   Wu, Mingming ^a   Liu, An ^a   Wang, Jun ^a   Zhu, Tao ^a   Luo, Zhaofeng ^a   Shan, Ge ^a  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Contrast screening; P53; Rna aptamer; SELEX; Tumor

Indexed keywords

AMINO ACID; APTAMER; MASPIN; POLO LIKE KINASE 2; PROTEIN BAX; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; PUMA PROTEIN; MUTANT PROTEIN; NANOPARTICLE;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; DRUG PROTEIN BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEK293 CELL LINE; HELA CELL LINE; HUMAN; HUMAN CELL; LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; TUNEL ASSAY; ANIMAL; CELL PROLIFERATION; CHEMISTRY; COMBINATORIAL CHEMISTRY; DRUG SCREENING; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR GENETICS; MOUSE; MUTATION; NEOPLASM; NUCLEOTIDE SEQUENCE; PATHOLOGY;

METAZOA; MUS;

ADMINISTRATION, INTRAVENOUS; AMINO ACID SUBSTITUTION; AMINO ACIDS; ANIMALS; APTAMERS, NUCLEOTIDE; BASE SEQUENCE; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEK293 CELLS; HELA CELLS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; MUTATION; NANOPARTICLES; NEOPLASMS; SELEX APTAMER TECHNIQUE; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84939197249     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1502159112     Document Type: Article

References (59)

1. Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249(4968):505-510.
2. Ellington AD, Szostak JW (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346(6287):818-822.
3. Bock LC, Griffin LC, Latham JA, Vermaas EH, Toole JJ (1992) Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 355(6360):564-566.
4. Huizenga DE, Szostak JW (1995) A DNA aptamer that binds adenosine and ATP. Biochemistry 34(2):656-665.
5. White RR, et al. (2003) Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc Natl Acad Sci USA 100(9):5028-5033.
6. McNamara JO, 2nd, et al. (2006) Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24(8):1005-1015.
7. Lou X, et al. (2009) Micromagnetic selection of aptamers in microfluidic channels. Proc Natl Acad Sci USA 106(9):2989-2994.
8. Mahlknecht G, et al. (2013) Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. Proc Natl Acad Sci USA 110(20):8170-8175.
9. Zhu G, et al. (2013) Self-assembled, aptamer-tethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics. Proc Natl Acad Sci USA 110(20):7998-8003.
10. Li L, et al. (2014) Aptamer photoregulation in vivo. Proc Natl Acad Sci USA 111(48): 17099-17103.
11. Sefah K, et al. (2014) In vitro selection with artificial expanded genetic information systems. Proc Natl Acad Sci USA 111(4):1449-1454.
12. van de Pavert SA, et al. (2007) A single amino acid substitution (Cys249Trp) in Crb1 causes retinal degeneration and deregulates expression of pituitary tumor transforming gene Pttg1. J Neurosci 27(3):564-573.
13. Pace JM, et al. (2002) A single amino acid substitution (D1441Y) in the carboxyl-terminal propeptide of the proalpha1(I) chain of type I collagen results in a lethal variant of osteogenesis imperfecta with features of dense bone diseases. J Med Genet 39(1):23-29.
14. Wong HY, Law PY, Ho YY (2007) Disease-associated Glut1 single amino acid substitute mutations S66F, R126C, and T295M constitute Glut1-deficiency states in vitro. Mol Genet Metab 90(2):193-198.
15. Bunn HF (1997) Pathogenesis and treatment of sickle cell disease. N Engl J Med 337(11):762-769.
16. Hrasćan R, et al. (1996) Concomitant point mutation of tumor suppressor gene p53 and oncogene c-N-ras in malignant neuroendocrine pancreatic tumor. Anticancer Res 16(6B):3761-3766.
17. Wong CC, et al.; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium (2014) Inactivating CUX1 mutations promote tumorigenesis. Nat Genet 46(1):33-38.
18. Hart JR, et al. (2015) The butterfly effect in cancer: A single base mutation can remodel the cell. Proc Natl Acad Sci USA 112(4):1131-1136.
19. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253(5015):49-53.
20. Cho Y, Gorina S, Jeffrey PD, Pavletich NP (1994) Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265(5170):346-355.
21. Bullock AN, Fersht AR (2001) Rescuing the function of mutant p53. Nat Rev Cancer 1(1):68-76.
22. Liu DP, Song H, Xu Y (2010) A common gain of function of p53 cancer mutants in inducing genetic instability. Oncogene 29(7):949-956.
23. Blandino G, Levine AJ, Oren M (1999) Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18(2):477-485.
24. Finlay CA, Hinds PW, Levine AJ (1989) The p53 proto-oncogene can act as a suppressor of transformation. Cell 57(7):1083-1093.
25. Hinds PW, et al. (1990) Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: A comparison of the "hot spot" mutant phenotypes. Cell Growth Differ 1(12):571-580.
26. Kogan-Sakin I, et al. (2011) Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ 18(2):271-281.
27. Goh HS, Yao J, Smith DR (1995) p53 point mutation and survival in colorectal cancer patients. Cancer Res 55(22):5217-5221.
28. Yang XZ, et al. (2012) Sheddable ternary nanoparticles for tumor acidity-targeted siRNA delivery. ACS Nano 6(1):771-781.
29. Phelps RM, et al. (1996) NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl 24:32-91.
30. Fábián Z, Vecsernyés M, Pap M, Szeberényi J (2006) The effects of a mutant p53 protein on the proliferation and differentiation of PC12 rat phaeochromocytoma cells. J Cell Biochem 99(5):1431-1441.
31. Rieber M, Strasberg-Rieber M (2014) p53 inactivation decreases dependence on estrogen/ERK signalling for proliferation but promotes EMT and susceptility to 3-bromopyruvate in ERα+ breast cancer MCF-7 cells. Biochem Pharmacol 88(2):169-177.
32. Muller PA, et al. (2009) Mutant p53 drives invasion by promoting integrin recycling. Cell 139(7):1327-1341.
33. Muller PA, Vousden KH, Norman JC (2011) p53 and its mutants in tumor cell migration and invasion. J Cell Biol 192(2):209-218.
34. Tsang WP, Ho FY, Fung KP, Kong SK, Kwok TT (2005) p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis. Int J Cancer 114(3):331-336.
35. Nicholson DW, et al. (1995) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376(6535):37-43.
36. Horvath MM, Wang X, Resnick MA, Bell DA (2007) Divergent evolution of human p53 binding sites: Cell cycle versus apoptosis. PLoS Genet 3(7):e127.
37. Dittmer D, et al. (1993) Gain of function mutations in p53. Nat Genet 4(1):42-46.
38. Müller M, et al. (1998) p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 188(11):2033-2045.
39. Löhr KL, Möritz C, Contente A, Dobbelstein M (2003) p21/CDKN1A mediates negative regulation of transcription by p53. J Biol Chem 278(35):32507-32516.
40. Burns TF, Fei P, Scata KA, Dicker DT, El-Deiry WS (2003) Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol 23(16):5556-5571.
41. Chipuk JE, et al. (2004) Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303(5660):1010-1014.
42. Kortlever RM, Higgins PJ, Bernards R (2006) Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol 8(8):877-884.
43. Oshiro MM, et al. (2003) Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression. Oncogene 22(23):3624-3634.
44. Lu X, Park SH, Thompson TC, Lane DP (1992) Ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell 70(1):153-161.
45. Lee YJ, Han SR, Maeng JS, Cho YJ, Lee SW (2012) In vitro selection of Escherichia coli O157:H7-specific RNA aptamer. Biochem Biophys Res Commun 417(1):414-420.
46. Shiratori I, et al. (2014) Selection of DNA aptamers that bind to influenza A viruses with high affinity and broad subtype specificity. Biochem Biophys Res Commun 443(1):37-41.
47. Shui B, et al. (2012) RNA aptamers that functionally interact with green fluorescent protein and its derivatives. Nucleic Acids Res 40(5):e39.
48. Olivier M, Hollstein M, Hainaut P (2010) TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2(1):a001008.
49. Martins CP, Brown-Swigart L, Evan GI (2006) Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127(7):1323-1334.
50. Ventura A, et al. (2007) Restoration of p53 function leads to tumour regression in vivo. Nature 445(7128):661-665.
51. Xue W, et al. (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445(7128):656-660.
52. Yu X, Vazquez A, Levine AJ, Carpizo DR (2012) Allele-specific p53 mutant reactivation. Cancer Cell 21(5):614-625.
53. Shan G, et al. (2008) A small molecule enhances RNA interference and promotes microRNA processing. Nat Biotechnol 26(8):933-940.
54. Shan G (2010) RNA interference as a gene knockdown technique. Int J Biochem Cell Biol 42(8):1243-1251.
55. Gragoudas ES, Adamis AP, Cunningham ET, Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351(27):2805-2816.
56. Ng EW, et al. (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5(2):123-132.
57. Sundaram P, Kurniawan H, Byrne ME, Wower J (2013) Therapeutic RNA aptamers in clinical trials. Eur J Pharm Sci 48(1-2):259-271.
58. Li Z, et al. (2015) Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol 22(3):256-264.
59. National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals (2011) Guide for the Care and Use of Laboratory Animals (National Academies Press, Washington, DC), 8th Ed.